Development, Characterization, and Pharmacokinetic Evaluation of a CRV431 Loaded Self-Microemulsifying Drug Delivery System.

CONCLUSIONS: The developed SMEDDS formulation should allow for effective clinical development of CRV431, targeted to the treatment of liver diseases including hepatitis B (HBV), fibrosis, and hepatocellular carcinoma. PMID: 30472978 [PubMed - in process]
Source: Journal of Pharmacy and Pharmaceutical Sciences - Category: Drugs & Pharmacology Tags: J Pharm Pharm Sci Source Type: research